Takeda Pharmaceuticals North America, Inc. Release: New Study Demonstrates That Lubiprostone May Improve Symptom Relief Rates in Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

WASHINGTON, D.C. -- (MARKET WIRE) -- May 21, 2007 -- A new study demonstrated that the active ingredient in AMITIZA® (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C). These results were presented as a late-breaker at Digestive Disease Week 2007, the largest annual international meeting of digestive disease specialists.